Prodotti competitors / Area Onco-Ema, Area Kite 6 dicembre 2024 Significant OS Benefit with Glofitamab plus gemcitabine–oxaliplatin (GemOx) in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL (STARGLO study)
